These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34841955)

  • 1. Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
    Sarkar P; Redondo J; Hares K; Bailey S; Georgievskaya A; Heesom K; Kemp KC; Scolding NJ; Rice CM
    Mult Scler; 2022 Jul; 28(8):1179-1188. PubMed ID: 34841955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis.
    Sarkar P; Redondo J; Kemp K; Ginty M; Wilkins A; Scolding NJ; Rice CM
    Cytotherapy; 2018 Jan; 20(1):21-28. PubMed ID: 28917625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis.
    Redondo J; Sarkar P; Kemp K; Heesom KJ; Wilkins A; Scolding NJ; Rice CM
    Stem Cells Transl Med; 2018 Oct; 7(10):748-758. PubMed ID: 30063300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Redondo J; Sarkar P; Kemp K; Virgo PF; Pawade J; Norton A; Emery DC; Guttridge MG; Marks DI; Wilkins A; Scolding NJ; Rice CM
    Mult Scler; 2018 Jun; 24(7):919-931. PubMed ID: 28548004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis.
    Petrou P; Kassis I; Ginzberg A; Hallimi M; Karussis D
    Stem Cells Transl Med; 2022 Mar; 11(1):55-58. PubMed ID: 35641166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
    Harris VK; Vyshkina T; Sadiq SA
    Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
    Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
    Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
    Wang Q; Chuikov S; Taitano S; Wu Q; Rastogi A; Tuck SJ; Corey JM; Lundy SK; Mao-Draayer Y
    Int J Mol Sci; 2015 Jun; 16(6):13885-907. PubMed ID: 26090715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.
    Harris VK; Faroqui R; Vyshkina T; Sadiq SA
    Stem Cells Transl Med; 2012 Jul; 1(7):536-47. PubMed ID: 23197858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
    Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis.
    Kassis I; Ben-Zwi M; Petrou P; Halimi M; Karussis D
    Immunol Lett; 2021 May; 233():11-19. PubMed ID: 33676976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.
    Harris VK; Yan QJ; Vyshkina T; Sahabi S; Liu X; Sadiq SA
    J Neurol Sci; 2012 Feb; 313(1-2):167-77. PubMed ID: 21962795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
    Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
    Trials; 2019 May; 20(1):263. PubMed ID: 31072380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretome analysis of human bone marrow derived mesenchymal stromal cells.
    Baberg F; Geyh S; Waldera-Lupa D; Stefanski A; Zilkens C; Haas R; Schroeder T; Stühler K
    Biochim Biophys Acta Proteins Proteom; 2019 Apr; 1867(4):434-441. PubMed ID: 30716505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease.
    Teixeira FG; Carvalho MM; Panchalingam KM; Rodrigues AJ; Mendes-Pinheiro B; Anjo S; Manadas B; Behie LA; Sousa N; Salgado AJ
    Stem Cells Transl Med; 2017 Feb; 6(2):634-646. PubMed ID: 28191785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.
    Kassis I; Petrou P; Halimi M; Karussis D
    Immunol Lett; 2013; 154(1-2):70-6. PubMed ID: 23994102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
    Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
    Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
    Suneetha A; Raja Rajeswari K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Induce Ischemic Neuroprotection by Modulating Leukocytes and Specifically Neutrophils.
    Wang C; Börger V; Sardari M; Murke F; Skuljec J; Pul R; Hagemann N; Dzyubenko E; Dittrich R; Gregorius J; Hasenberg M; Kleinschnitz C; Popa-Wagner A; Doeppner TR; Gunzer M; Giebel B; Hermann DM
    Stroke; 2020 Jun; 51(6):1825-1834. PubMed ID: 32312217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.